A Study of IMC-1 In Patients With Fibromyalgia



Status:Completed
Conditions:Chronic Pain, Chronic Pain, Fibromyalgia, Pain
Therapuetic Areas:Musculoskeletal, Rheumatology
Healthy:No
Age Range:18 - 70
Updated:10/19/2013
Start Date:May 2013
End Date:May 2014
Contact:Mark Schmal
Email:mark.schmal@premier-research.com

Use our guide to learn which trials are right for you!

A Double-Blinded, Randomized, Placebo-Controlled, Proof of Concept Phase 2a Study Exploring the Safety and Efficacy of IMC-1 for the Treatment of Patients With Fibromyalgia


This is a randomized, double-blind, placebo-controlled, 16-week study designed to evaluate
the hypothesis that tissue-resident herpes virus may be causally related to fibromyalgia
symptoms or recurrence. IMC-1 is a combination treatment that is designed to suppress this
suspected virus and thus alleviate fibromyalgia symptoms.


Inclusion Criteria:

- Diagnosis of fibromyalgia

- English speaker

Exclusion Criteria:

- Rheumatologic diseases

- Bipolar disease, OCD, severe anxiety, schizophrenia

- Systemic infection, severe cardiac disease, chronic steroid usage

- chronic opioid usage
We found this trial at
8
sites
Raleigh, North Carolina
?
mi
from
Raleigh, NC
Click here to add this to my saved trials
Ann Arbor, Michigan
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Birmingham, Alabama
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evansville, Indiana
?
mi
from
Evansville, IN
Click here to add this to my saved trials
Jacksonville, Florida
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Medford, Oregon
?
mi
from
Medford, OR
Click here to add this to my saved trials
Sacramento, California
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
Salt Lake City, Utah
?
mi
from
Salt Lake City, UT
Click here to add this to my saved trials